German pharmaceuticals-and-chemicals company Merck KGaA on Thursday posted higher 2021 earnings and sales, driven by its life science division, and proposed a higher dividend.
The company--which had raised its guidance three times over the course of 2021--posted after-tax profit of 3.07 billion euros ($3.41 billion) for the year, up from EUR1.99 billion the year prior.
Ebitda pre--a closely-watched company metric which measures earnings before interest, taxes, depreciation and amortization before one-time items--was EUR6.10 billion in the year, up from EUR5.20 billion the year before, Merck said.
Net sales came in at EUR19.69 billion compared with EUR17.53 billion the year prior, the company said.
Looking ahead, Merck expects strong organic growth in net sales and Ebitda pre in 2022, driven by all business sectors but particularly by its life science division.
The company proposed a dividend raise of EUR0.45 to EUR1.85, which it said was an all-time high.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.